← Leaderboards
Filippo G Giancotti
Sloan-Kettering Institute For Cancer Res
$26,283,563
Attributed
$27,381,756
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–22$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$27,381,756 · 14
By mechanism
R01$14,311,245 · 8
R35$6,686,684 · 1
P01$3,287,398 · 2
R37$3,040,429 · 1
R13$56,000 · 2
Top collaborators
- Marjorie G. Zauderer5 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Harold E Varmus$14,554,892
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionCellsMediatingMouse ModelIntegrinsSignal PathwayIn VivoMalignant NeoplasmsPathway InteractionsTumorMutantNeoplastic CellResponseCancer CellGrowthBaseOncogenicMalignant Breast NeoplasmNeoplasm MetastasisBiochemicalMolecularTumorigenesisIn VitroPlay
Grant awards (61)
Mechanisms governing metastatic dormancy and reactivation$955,499
R35 · FY2022 · CA · contact PI
Mechanisms governing metastatic dormancy and reactivation$959,994
R35 · FY2021 · CA · contact PI
Mechanisms governing metastatic dormancy and reactivation$1
R35 · FY2021 · CA · contact PI
Mechanisms governing metastatic dormancy and reactivation$959,998
R35 · FY2020 · CA · contact PI
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma$313,142
R01 · FY2020 · CA · contact PI
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma$182,854
R01 · FY2020 · CA · contact PI
Mechanisms governing metastatic dormancy and reactivation$931,198
R35 · FY2019 · CA · contact PI
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma$481,115
R01 · FY2019 · CA · contact PI
Mechanisms governing metastatic dormancy and reactivation$959,998
R35 · FY2018 · CA · contact PI
RNDI- Mediated Breast Cancer Suppression$505,589
P01 · FY2018 · CA · contact PI
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma$495,996
R01 · FY2018 · CA · contact PI
Mechanisms governing metastatic dormancy and reactivation$959,998
R35 · FY2017 · CA · contact PI
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma$510,996
R01 · FY2017 · CA · contact PI
RNDI- Mediated Breast Cancer Suppression$504,912
P01 · FY2017 · CA · contact PI
Mechanisms governing metastatic dormancy and reactivation$959,998
R35 · FY2016 · CA · contact PI
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma$525,425
R01 · FY2016 · CA · contact PI
RNDI- Mediated Breast Cancer Suppression$508,979
P01 · FY2016 · CA · contact PI
RNDI- Mediated Breast Cancer Suppression$509,318
P01 · FY2015 · CA · contact PI
Mechanisms governing metastatic reactivation of breast cancer.$440,646
R01 · FY2015 · CA · contact PI
Rho GTPases and polarity signaling pathways in morphogenesis and migration$676,741
R01 · FY2014 · GM · contact PI
Mechanism of Merlin-mediated contact inhibition and tumor suppression.$464,660
R01 · FY2014 · CA · contact PI
Mechanisms governing metastatic reactivation of breast cancer.$427,427
R01 · FY2014 · CA · contact PI
Mechanism of Merlin-mediated contact inhibition and tumor suppression.$452,070
R01 · FY2013 · CA · contact PI
Mechanisms governing metastatic reactivation of breast cancer.$440,646
R01 · FY2013 · CA · contact PI
INTEGRIN SIGNALING DURING BREAST TUMORIGENESIS$355,237
R01 · FY2013 · CA · contact PI
Mechanism of Merlin-mediated contact inhibition and tumor suppression.$547,633
R01 · FY2012 · CA · contact PI
Mouse Models for Tumor Progression and Maintenance$415,238
P01 · FY2012 · CA · contact PI
INTEGRIN SIGNALING DURING BREAST TUMORIGENESIS$377,912
R01 · FY2012 · CA · contact PI
Mechanism of Merlin-mediated contact inhibition and tumor suppression.$550,538
R01 · FY2011 · CA · contact PI
Mouse Models for Tumor Progression and Maintenance$415,260
P01 · FY2011 · CA · contact PI
INTEGRIN SIGNALING DURING BREAST TUMORIGENESIS$377,912
R01 · FY2011 · CA · contact PI
Mechanism of Merlin-mediated contact inhibition and tumor suppression.$464,707
R01 · FY2010 · CA · contact PI
Mouse Models for Tumor Progression and Maintenance$428,102
P01 · FY2010 · CA · contact PI
Molecular Analysis of the alpha6beta4 Integrin$410,916
R37 · FY2010 · CA · contact PI
Integrin alpha6beta4 Signaling in Prostate Carcinoma Growth and Invasion$402,635
R01 · FY2010 · CA · contact PI
INTEGRIN SIGNALING DURING BREAST TUMORIGENESIS$389,600
R01 · FY2010 · CA · contact PI
2010 NF Conference$46,000
R13 · FY2010 · NS · contact PI
Molecular Analysis of the alpha6beta4 Integrin$410,916
R37 · FY2009 · CA · contact PI
INTEGRIN SIGNALING DURING BREAST TUMORIGENESIS$393,420
R01 · FY2009 · CA · contact PI
Integrin alpha6beta4 Signaling in Prostate Carcinoma Growth and Invasion$392,977
R01 · FY2009 · CA · contact PI
Molecular Analysis of the alpha6beta4 Integrin$410,916
R37 · FY2008 · CA · contact PI
Integrin alpha6beta4 Signaling in Prostate Carcinoma Growth and Invasion$383,595
R01 · FY2008 · CA · contact PI
Molecular Analysis of the alpha6beta4 Integrin$389,561
R37 · FY2007 · CA · contact PI
Integrin alpha6beta4 Signaling in Prostate Carcinoma Growth and Invasion$381,906
R01 · FY2007 · CA · contact PI
Role of the Adaptor Protein Shc in Integrin Signaling$366,188
R01 · FY2007 · CA · contact PI
Integrin alpha6beta4 Signaling in Prostate Carcinoma Growth and Invasion$387,389
R01 · FY2006 · CA · contact PI
Molecular Analysis of the alpha6beta4 Integrin$348,245
R37 · FY2006 · CA · contact PI
Role of the Adaptor Protein Shc in Integrin Signaling$348,003
R01 · FY2006 · CA · contact PI
Molecular Analysis of the alpha6beta4 Integrin$356,625
R37 · FY2005 · CA
Role of the Adaptor Protein Shc in Integrin Signaling$356,378
R01 · FY2005 · CA
Molecular Analysis of the alpha6beta4 Integrin$356,625
R37 · FY2004 · CA
Role of the Adaptor Protein Shc in Integrin Signaling$356,378
R01 · FY2004 · CA
Molecular Analysis of the alpha6beta4 Integrin$356,625
R37 · FY2003 · CA
Role of the Adaptor Protein Shc in Integrin Signaling$355,109
R01 · FY2003 · CA
MOLECULAR ANALYSIS OF THE ALPHA6-BETA4 INTEGRIN$303,594
R01 · FY2002 · CA
ADAPTOR PROTEIN SHC AND INTEGRIN SIGNALING$279,423
R01 · FY2002 · CA
MOLECULAR ANALYSIS OF THE ALPHA6-BETA4 INTEGRIN$297,418
R01 · FY2001 · CA
ADAPTOR PROTEIN SHC AND INTEGRIN SIGNALING$273,131
R01 · FY2001 · CA
MOLECULAR ANALYSIS OF THE ALPHA6-BETA4 INTEGRIN$291,422
R01 · FY2000 · CA
ADAPTOR PROTEIN SHC AND INTEGRIN SIGNALING$267,022
R01 · FY2000 · CA
SIGNALING BY ADHESION RECEPTORS$10,000
R13 · FY2000 · CA